Javascript is not activated in your browser. This website needs javascript activated to work properly.
You are here

Abberant cytogenetic evolution pattern of Philadelphia-positive chronic myeloid leukemia treated with interferon-alpha

  • B Johansson
  • Thoas Fioretos
  • R Billstrom
  • Felix Mitelman
Publishing year: 1996
Language: English
Pages: 1134-1138
Publication/Series: Leukemia
Volume: 10
Issue: 7
Document type: Journal article
Publisher: Nature Publishing Group

Abstract english

The cytogenetic evolution of 32 Philadelphia (Ph)-positive chronic myeloid leukemias (CML) receiving interferon-alpha (IFN-alpha) therapy was compared to the patterns in untreated CML and cases treated with busulfan (Bu), hydroxyurea (Hy), and allogeneic bone marrow transplantation (BMT). Half of the CML receiving IFN-alpha had at least one of the well-known major or minor route aberrations whereas 16 cases displayed unusual secondary abnormalities, of which only del(7p) and del(13q) were recurrent; a frequency significantly higher than in CML without therapy or after Bu and Hy treatment (P < 0.001) but similar to the one found post-BMT. The incidence of cases with cytogenetically divergent subclones, ie cell populations with unrelated aberrations in addition to the t(9;22), was also higher in the IFN-alpha group compared to the untreated, Bu and Hy groups (P < 0.01) but similar to the post-BMT group. Finally, 14 of the 32 IFN-alpha-treated CML displayed cytogenetic evolution already during the chronic phase; again a higher incidence than in the untreated, Bu and Hy groups (P < 0.001) but not different from the post-BMT group. These findings strongly indicate that IFN-alpha, directly or indirectly, can induce clones with aberrant chromosomal evolution patterns to evolve and proliferate, but the mechanisms underlying these cytogenetic peculiarities remain to be elucidated.


  • Cancer and Oncology


  • ISSN: 1476-5551
Thoas Fioretos
E-mail: thoas [dot] fioretos [at] med [dot] lu [dot] se

Research team manager

Translational Genomic and Functional Studies of Leukemia

+46 46 222 45 95

+46 70 334 33 67



Division of Clinical Genetics

+46 46 222 45 95

+46 70 334 33 67